Bisphosphonate Liposomes for Cobalt and Strontium Decorporation?Géraldine Landon1,Guillaume Phan1,François Fay2,David Suhard1,David Broggio1,Raphaël Bô1,Céline Bouvier-Capely1,Elias Fattal2(1....Bisphosphonate Liposomes for Cobalt and Strontium Decorporation?Géraldine Landon1,Guillaume Phan1,François Fay2,David Suhard1,David Broggio1,Raphaël Bô1,Céline Bouvier-Capely1,Elias Fattal2(1.Health Division,Institute for Radiological Protection and Nuclear Safety(IRSN),Fontenay-aux-Roses,France;2.UniversitéParis-Saclay,CNRS,Institut Galien Paris-Saclay,91400 Orsay,France)Abstract:During a nuclear/radiological incident or an accident involving internal intakes with radioactive cobalt or strontium,the recommended treatments,consisting of the administration of diethylenetriaminepentaacetic acid for^(60)Co and calcium gluconate for^(90)Sr,are of low specificity,and their effectiveness can be enhanced.In this manuscript,a liposomal formulation was developed to deliver potential chelating agents to the main retention organs of both radionuclides.A bisphosphonate,etidronate,has been selected as a possible candidate due to its satisfying decorporation activity for uranium,bone tropism,and potential affinity with cobalt.Pre-clinical studies have been carried out on rats using radionuclide contamination and treatment administration by the intravenous route.展开更多
文摘Bisphosphonate Liposomes for Cobalt and Strontium Decorporation?Géraldine Landon1,Guillaume Phan1,François Fay2,David Suhard1,David Broggio1,Raphaël Bô1,Céline Bouvier-Capely1,Elias Fattal2(1.Health Division,Institute for Radiological Protection and Nuclear Safety(IRSN),Fontenay-aux-Roses,France;2.UniversitéParis-Saclay,CNRS,Institut Galien Paris-Saclay,91400 Orsay,France)Abstract:During a nuclear/radiological incident or an accident involving internal intakes with radioactive cobalt or strontium,the recommended treatments,consisting of the administration of diethylenetriaminepentaacetic acid for^(60)Co and calcium gluconate for^(90)Sr,are of low specificity,and their effectiveness can be enhanced.In this manuscript,a liposomal formulation was developed to deliver potential chelating agents to the main retention organs of both radionuclides.A bisphosphonate,etidronate,has been selected as a possible candidate due to its satisfying decorporation activity for uranium,bone tropism,and potential affinity with cobalt.Pre-clinical studies have been carried out on rats using radionuclide contamination and treatment administration by the intravenous route.
